Brand name: Crestor
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on rosuvastatin (Crestor)
- Statement Regarding the FDA’s Decision to Leave Rosuvastatin (Crestor) on the Market, March 14, 2005
- Letter Demonstrating that Rosuvastatin (Crestor) Has Higher Rates of Rhabdomyolysis Compared to Other Statins, March 10, 2005
- Letter Urging Action on AstraZeneca’s Misleading Crestor Advertising, November 24, 2004
- Letter Renewing Call for Rosuvastatin (Crestor) Ban, October 29, 2004
- Letter Calling for Criminal Investigation of AstraZeneca, August 3, 2004
- Letter in the Lancet: Dangers of Rosuvastatin (Crestor) Identified Before and After FDA Approval, June 26, 2004
- Letter Urging Ban of Cholesterol-Lowering Drug Rosuvastatin (Crestor), May 18, 2004
- Petition to Ban Cholesterol-Lowering Drug Rosuvastatin (Crestor), March 4, 2004
- Testimony on Rosuvastatin (Crestor), July 9, 2003